I think it's important to remember that the public has only been provided relatively superficial interim results from 5 patients and that this is still an early-stage biotech investment, so it's highly speculative. Data in humans with a lack of serious adverse events will win out, or lose out, in the long run. The price now reflects the data shared by the company so far. We've still got quite a ways to go to prove that DurAVR is superior.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$6.27 |
Change
0.360(6.09%) |
Mkt cap ! $97.17M | |||
| Open | High | Low | Value | Volume |
| $5.93 | $6.30 | $5.91 | $107.9K | 17.39K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3500 | $6.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.27 | 200 | 1 |
View Market Depth
| Last trade - 15.42pm 27/06/2025 (20 minute delay) ? |
| AVR (ASX) Chart |